13 June 2022 June 2022 decisions news release Advice on four new medicines published by SMC The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday June 13) published advice on four new medicines.
9 May 2022 May 2022 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday May 9) published advice on eight new medicines.
11 April 2022 April 2022 decisions news release Advice on three new medicines has today (Monday 11 April) been published by the Scottish Medicines Consortium.
8 March 2022 New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines A new UK-wide health technology assessment access forum has been developed by partners including the Scottish Medicines Consortium (SMC) as part of the Innovative Licensing and Access Pathway (ILAP).
7 March 2022 March 2022 decisions news release Medicines for an aggressive form of breast cancer, advanced lung cancer, endometrial cancer and the rare condition, hereditary angioedema, accepted by SMC. The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday March 7) published advice on seven new medicines.
7 February 2022 February 2022 decisions news release Medicines for lung cancer due to previous asbestos Medicines for lung cancer due to previous asbestos exposure and for a severely disabling muscle wasting disease among six accepted for use by Scottish Medicines Consortiumaccepted for use by Scottish Medicines Consortium Advice on six new medicines for use in conditions including a rare lung cancer caused by occupational exposure to asbestos and also for a severely disabling muscle wasting disease has today (Monday 7 February) been published by the Scottish Medicines Consortium (SMC).
17 January 2022 January 2022 decisions news release Medicines for advanced breast cancer and non-small cell lung cancer accepted for use by Scottish Medicines Consortium Advice on four new medicines for use in conditions including advanced breast cancer and non-small cell lung cancer has today (Monday 17 January) been published by the Scottish Medicines Consortium (SMC).
13 December 2021 December 2021 decisions news release SMC accepts six new medicines for use by NHSScotland SMC accepts six new medicines for use by NHSScotland
8 November 2021 November 2021 decisions news release SMC accepts three new medicines for use by NHSScotland SMC accepts three new medicines for use by NHSScotland
22 October 2021 NICE Multiple Technology Appraisal (MTA) Healthcare Improvement Scotland advises on adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed.
